A third drug either FDA approved or showing clinical benefit for Alzheimer's disease confirms that the world of AD treatment has changed forever.
FDA upgrades Leqembi for AD from accelerated to traditional approval based on latest clinical data.
A new treatment for Alzheimer's Disease is promising, but we're not there yet.
Monoclonal antibodies to prevent sickle cell crises represents the promise and difficulties of high tech medical treatment.
A recent clinical trial tested a new approach to malaria prevention involving monoclonal antibodies.